28181464|t|Physicochemical characterization of chitosan - hyaluronan -coated solid lipid nanoparticles for the targeted delivery of paclitaxel: a proof-of-concept study in breast cancer cells
28181464|a|To investigate the potential of modified solid lipid nanoparticles (SLN) for the delivery of paclitaxel (PAX). SLN loaded with PAX were prepared via modified high-pressure hot homogenization. Formulation parameters were optimized to obtain a high-quality delivery system. SLN cores were coated, layer-by-layer, with a chitosan and hyaluronan (HA) shell. Selectivity toward HA receptors was tested in a breast cancer cell line, MCF-7. Stable and reproducible nano-sized and negatively charged nanoparticles resulted. Findings reveal that chitosan - HA -coated SLN facilitated the targeting, cellular uptake and the time-/dose-controlled delivery and release of PAX, enhancing intrinsic chemotherapeutic activities. SLN are suitable carrier candidates for nano-oncology given their localized, and potent cytotoxic potential overcoming multidrug-resistant cancer cells.
28181464	36	44	chitosan	T109,T121	C0162969
28181464	47	57	hyaluronan	T109,T121,T123	C0813622
28181464	72	91	lipid nanoparticles	T203	C1709148
28181464	109	117	delivery	T061	C0565867
28181464	121	131	paclitaxel	T109,T121	C0144576
28181464	135	157	proof-of-concept study	T062	C2603343
28181464	161	180	breast cancer cells	T025	C1512505
28181464	222	247	solid lipid nanoparticles	T203	C1709148
28181464	249	252	SLN	T203	C1709148
28181464	274	284	paclitaxel	T109,T121	C0144576
28181464	286	289	PAX	T109,T121	C0144576
28181464	292	311	SLN loaded with PAX	T109,T121	C3898158
28181464	339	371	high-pressure hot homogenization	T059	C3828864
28181464	373	395	Formulation parameters	T062	C0524527
28181464	423	451	high-quality delivery system	T074	C0085104
28181464	453	456	SLN	T203	C1709148
28181464	468	490	coated, layer-by-layer	T080	C1522408
28181464	499	507	chitosan	T109,T121	C0162969
28181464	512	522	hyaluronan	T109,T121,T123	C0813622
28181464	524	526	HA	T109,T121,T123	C0813622
28181464	554	556	HA	T109,T121,T123	C0813622
28181464	557	566	receptors	T116,T192	C0597357
28181464	583	606	breast cancer cell line	T025	C1512505
28181464	608	613	MCF-7	T025	C0596890
28181464	615	638	Stable and reproducible	T080	C0205556
28181464	639	649	nano-sized	T080	C0205556
28181464	654	686	negatively charged nanoparticles	T073	C1450054
28181464	718	726	chitosan	T109,T121	C0162969
28181464	729	731	HA	T109,T121,T123	C0813622
28181464	740	743	SLN	T203	C1709148
28181464	760	769	targeting	T169	C1521840
28181464	771	786	cellular uptake	T043	C3888108
28181464	795	837	time-/dose-controlled delivery and release	T203	C1616334
28181464	841	844	PAX	T109,T121	C0144576
28181464	856	893	intrinsic chemotherapeutic activities	T061	C0870057
28181464	895	898	SLN	T203	C1709148
28181464	912	930	carrier candidates	T074	C1706209
28181464	935	948	nano-oncology	T091	C0278627
28181464	983	1002	cytotoxic potential	T121	C0304497
28181464	1003	1013	overcoming	T033	C0243095
28181464	1014	1046	multidrug-resistant cancer cells	T038	C0282588